Morning Market Gainers

shares jumped 62.74 percent to $12.71 after announcing positive top-line results from a Phase 2 study of Vadadustat "in Dialysis Patients with Anemia Related to Chronic Kidney Disease."

shares climbed 42.94 percent to $11.34 after making public the positive top-line results it achieved "from its Phase 1 single ascending dose clinical study of VTP-43742 in autoimmune disorders."

rose 17.48 percent to $10.35. TRC reported Q4 earnings of $0.22 per share on revenue of $114.6 million.

shares gained 14.30 percent to $4.68 after the company reported that ARX-04 has met all endpoints in PIVOTAL Phase 3 study for moderate-to-severe acute pain.

shares jumped 8.55 percent to $32.50 following Q2 results and a $1.4 billion securitization plan focused on retail installment contract. The company named Norman Miller as CEO and President, and also announced a new $75 million buyback plan.

rose 8.02 percent to $40.36 after the company reported stronger-than-expected results for its second quarter.

gained 3.74 percent to $0.970 following announcement that Quell Wearable Pain Relief Device is now available on Amazon.